Needham analyst Serge Belanger initiated coverage of MoonLake Immunotherapeutics with a Buy rating and $76 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MLTX:
- Largest borrow rate increases among liquid names
- MoonLake Immunotherapeutics reports Q2 EPS (23c), consensus (27c)
- MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
- Three new option listings on August 9th
- MoonLake Immunotherapeutics price target raised to $86 from $61 at Wedbush